GlassScriptPhysician profile
Guyle P Donham
NPI 1659386001
$8,989.05
in general payments reported to CMS, 2019-2025
53 companies · $900 in 2025
The $900 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $767 · 2021: $1,288 · 2022: $1,705 · 2023: $1,830 · 2024: $1,380 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,109.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,215.59 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $853.89 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $751.92 | 2019-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.31 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $575.86 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $558.05 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $536.13 | 2019-2024 | Farxiga, Airsupra, Tezspire |
| Horizon Therapeutics Plc | $360.09 | 2020-2023 | Krystexxa |
| Astellas Pharma US INC | $319.70 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $206.26 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $200.85 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $197.74 | 2019-2025 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $192.81 | 2023-2025 | Qelbree, Qelbree |
| Allergan, INC. | $185.43 | 2019-2020 | |
| Eisai INC. | $176.90 | 2020-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guyle Donham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.